[Form 4] Astera Labs, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Astera Labs director Jack R. Lazar reported automatic sales of common stock under a Rule 10b5-1 trading plan adopted May 28, 2025. On 08/27/2025 the Form 4 shows five sale transactions totaling 22,500 shares sold in multiple trades at weighted-average prices ranging from about $176.73 to $183.09. The filing lists the reporter's beneficial ownership following the reported sales as 97,351 shares held directly. The Form 4 was signed by an attorney-in-fact on 08/28/2025 and includes footnotes disclosing price ranges for each grouped sale.

Positive

• Sales executed under a documented Rule 10b5-1 plan, which supports procedural compliance and an affirmative-defense record
• Detailed disclosure of weighted-average prices and price ranges with an undertaking to provide per-trade price information on request
• Reporting person remains a director and retains 97,351 shares after the reported transactions

Negative

• Director sold a total of 22,500 shares on 08/27/2025, reducing direct holdings
• Multiple sales at varying prices may be interpreted by some market participants as a notable insider disposition (no further context provided)

Insights

Corporate Governance Expert

TL;DR: Insiders used a pre-established 10b5-1 plan to sell a block of shares, preserving procedural compliance and transparency.

The Form 4 documents that Director Jack R. Lazar executed multiple automated sales under a Rule 10b5-1 plan adopted on May 28, 2025, which helps establish an affirmative defense against insider trading claims. The filing discloses weighted-average prices and price ranges for the grouped transactions and shows continuing direct ownership of 97,351 shares after the sales. From a governance standpoint, the filing is complete in that it identifies the 10b5-1 plan, reports granular sale volumes, and provides undertakings to supply transaction-level price details on request.

Securities Analyst

TL;DR: The sales are material in size but appear routine under a trading plan; no new company operational information is disclosed.

The transaction data show five sales on 08/27/2025 totaling 22,500 shares at weighted-average prices between approximately $176.73 and $183.09, leaving the reporting person with 97,351 shares. The filing contains explanatory footnotes on price ranges and a commitment to provide detailed execution information if requested. There is no additional financial or operational data in the Form 4 that would alter company valuation or outlook; the record simply updates insider holdings and executed sales method (10b5-1).

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAZAR JACK R

(Last) (First) (Middle)

C/O ASTERA LABS, INC.

2345 NORTH FIRST STREET

(Street)

SAN JOSE CA 95131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Astera Labs, Inc. [ ALAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2025		S(1)		1,553	D	$176.7342(2)	118,298	D
Common Stock	08/27/2025		S(1)		8,718	D	$177.7289(3)	109,580	D
Common Stock	08/27/2025		S(1)		8,706	D	$178.8253(4)	100,874	D
Common Stock	08/27/2025		S(1)		3,450	D	$179.7885(5)	97,424	D
Common Stock	08/27/2025		S(1)		73	D	$183.0903(6)	97,351	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $176.2100 to $177.0500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $177.3100 to $178.2800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $178.3200 to $179.3050, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $179.3800 to $180.1100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $182.3100 to $183.2000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Philip Mazzara, Attorney-in-Fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Astera Labs (ALAB) director Jack R. Lazar report on Form 4?

He reported automatic sales of 22,500 shares on 08/27/2025 executed under a Rule 10b5-1 trading plan; beneficial ownership after the sales is 97,351 shares.

Were the sales part of a 10b5-1 trading plan for ALAB?

Yes. The Form 4 states the sales occurred automatically pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 28, 2025.

How many separate sale entries are disclosed and what prices were reported?

Five sale entries are listed with weighted-average prices reported as approximately $176.73, $177.73, $178.83, $179.79, and $183.09, each supported by footnote price ranges.

Who signed the Form 4 and when was it filed?

The Form 4 was signed by Philip Mazzara, Attorney-in-Fact and dated 08/28/2025 in the signature block.

Does the Form 4 provide per-trade execution details for the reported sales?

Not in the filing itself. The filing reports weighted-average prices and price ranges and states the reporting person will provide full per-trade execution details to the issuer, any security holder, or the SEC staff upon request.